Two Enterococcus faecium Isolates Demonstrated Modulating Effects on the Dysbiosis of Mice Gut Microbiota Induced by Antibiotic Treatment.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101092791 Publication Model: Electronic Cited Medium: Internet ISSN: 1422-0067 (Electronic) Linking ISSN: 14220067 NLM ISO Abbreviation: Int J Mol Sci Subsets: MEDLINE

Original Publication: Basel, Switzerland : MDPI, [2000-

Enterococcus faecium* ; Dysbiosis*/microbiology ; Gastrointestinal Microbiome*/drug effects ; Anti-Bacterial Agents*/pharmacology; Animals ; Mice ; Feces/microbiology ; Fatty Acids, Volatile/metabolism ; Probiotics/pharmacology ; Dogs ; Bacteriocins/pharmacology

Broad-spectrum antibiotics are frequently used to treat bacteria-induced infections, but the overuse of antibiotics may induce the gut microbiota dysbiosis and disrupt gastrointestinal tract function. Probiotics can be applied to restore disturbed gut microbiota and repair abnormal intestinal metabolism. In the present study, two strains of Enterococcus faecium (named DC-K7 and DC-K9) were isolated and characterized from the fecal samples of infant dogs. The genomic features of E. faecium DC-K7 and DC-K9 were analyzed, the carbohydrate-active enzyme (CAZyme)-encoding genes were predicted, and their abilities to produce short-chain fatty acids (SCFAs) were investigated. The bacteriocin-encoding genes in the genome sequences of E. faecium DC-K7 and DC-K9 were analyzed, and the gene cluster of Enterolysin-A, which encoded a 401-amino-acid peptide, was predicted. Moreover, the modulating effects of E. faecium DC-K7 and DC-K9 on the gut microbiota dysbiosis induced by antibiotics were analyzed. The current results demonstrated that oral administrations of E. faecium DC-K7 and DC-K9 could enhance the relative abundances of beneficial microbes and decrease the relative abundances of harmful microbes. Therefore, the isolated E. faecium DC-K7 and DC-K9 were proven to be able to alter the gut microbiota dysbiosis induced by antibiotic treatment.

Lancet Gastroenterol Hepatol. 2020 Jul;5(7):658-666. (PMID: 32277872)
Sci Immunol. 2016 Sep;1(3):. (PMID: 28580440)
Adv Sci (Weinh). 2023 Oct;10(28):e2300822. (PMID: 37552813)
Annu Rev Physiol. 2010;72:297-313. (PMID: 20148677)
Microbiol Res. 2022 Mar;256:126954. (PMID: 34973546)
Nat Microbiol. 2016 Mar 07;1:16024. (PMID: 27572443)
Nature. 2015 Jan 8;517(7533):205-8. (PMID: 25337874)
Benef Microbes. 2019 Apr 19;10(3):225-236. (PMID: 30827150)
Front Microbiol. 2022 Apr 19;13:872230. (PMID: 35516435)
Gut Microbes. 2020;11(2):158-171. (PMID: 31595814)
Front Immunol. 2018 May 09;9:1040. (PMID: 29868005)
Front Microbiol. 2018 Jan 30;9:78. (PMID: 29441056)
FEMS Microbiol Rev. 2020 Jul 1;44(4):454-489. (PMID: 32556166)
Microbiome. 2022 Oct 14;10(1):171. (PMID: 36242064)
Am J Physiol Gastrointest Liver Physiol. 2015 Oct 1;309(7):G602-7. (PMID: 26272259)
Elife. 2019 Apr 10;8:. (PMID: 30969170)
Food Chem. 2017 Nov 1;234:494-501. (PMID: 28551266)
Appl Microbiol Biotechnol. 2017 Aug;101(15):6155-6164. (PMID: 28634850)
Sci Rep. 2017 Feb 06;7:41395. (PMID: 28165001)
Nat Rev Microbiol. 2011 Apr;9(4):233-43. (PMID: 21358670)
Nat Commun. 2016 Jan 26;7:10410. (PMID: 26811868)
J Immunol Res. 2017;2017:6976935. (PMID: 29250559)
JPEN J Parenter Enteral Nutr. 2013 Nov;37(6):763-74. (PMID: 23630018)
JCI Insight. 2020 May 7;5(9):. (PMID: 32302292)
Food Funct. 2021 Apr 7;12(7):3104-3119. (PMID: 33725036)
Curr Opin Biotechnol. 2020 Feb;61:226-234. (PMID: 32087535)
Gut. 2013 Nov;62(11):1591-601. (PMID: 23236009)
Front Cell Infect Microbiol. 2023 Jan 30;13:1069954. (PMID: 36794003)
Nutrients. 2013 May 29;5(6):1869-912. (PMID: 23760057)
Benef Microbes. 2018 Sep 18;9(5):743-754. (PMID: 30099892)
Gut Pathog. 2020 Sep 09;12:41. (PMID: 32944084)
Open Med. 2013 May 28;7(2):e56-67. (PMID: 24348885)
Sci Transl Med. 2016 Jun 15;8(343):343ra82. (PMID: 27306664)
Nat Rev Gastroenterol Hepatol. 2018 Apr;15(4):197-205. (PMID: 29362469)
Gut Microbes. 2021 Jan-Dec;13(1):1-16. (PMID: 33382952)
Am J Gastroenterol. 2023 Jul 1;118(7):1256-1267. (PMID: 36717369)
Cochrane Database Syst Rev. 2019 Apr 30;4:CD004827. (PMID: 31039287)
J Comput Biol. 2012 May;19(5):455-77. (PMID: 22506599)
Environ Microbiol. 2017 Jan;19(1):29-41. (PMID: 27928878)
Nucleic Acids Res. 2018 Jul 2;46(W1):W278-W281. (PMID: 29788290)
Sci Transl Med. 2016 Jun 15;8(343):343ra81. (PMID: 27306663)
Trends Microbiol. 2019 Dec;27(12):997-1010. (PMID: 31474424)
Nat Methods. 2015 Jan;12(1):59-60. (PMID: 25402007)
Nature. 2016 Dec 8;540(7632):280-283. (PMID: 27798599)
Animals (Basel). 2022 Sep 18;12(18):. (PMID: 36139326)
Clin Microbiol Rev. 2021 Dec 15;34(4):e0032320. (PMID: 34259567)
Trends Microbiol. 2016 Jun;24(6):463-476. (PMID: 26897710)
Gut Microbes. 2019;10(3):382-397. (PMID: 30409105)
Mol Biol Evol. 2021 Apr 13;38(4):1330-1338. (PMID: 33179739)
Appl Environ Microbiol. 2003 May;69(5):2975-84. (PMID: 12732574)
Sci Rep. 2018 Aug 23;8(1):12649. (PMID: 30139941)
Clin Nutr. 2021 Jan;40(1):64-71. (PMID: 32451125)
Lett Appl Microbiol. 2023 Mar 1;76(3):. (PMID: 36918202)
Bioinformatics. 2015 Feb 15;31(4):587-9. (PMID: 25338718)

32273056 National Natural Science Foundation of China

Keywords: Enterococcus faecium; antibiotic; bacteriocin; gut microbiota; probiotic; short-chain fatty acids

0 (Anti-Bacterial Agents)
0 (Fatty Acids, Volatile)
0 (Bacteriocins)

Date Created: 20240525 Date Completed: 20240525 Latest Revision: 20240527

20240527

PMC11121104

10.3390/ijms25105405

38791443